Regeneron’s Arcalyst Fails to Win Panel Backing for Gout - Bloomberg

Gout treatments include Takeda Pharmaceutical Co. (4502)’s Uloric and a generic version allopurinol. They lower levels of uric acid, or bodily waste, that cause gout in excess levels, which manifests through joint pain, according to the ...

BioCryst (Nasdaq: BCRX) Provides Corporate Update and Reports Q1 2012 Financial Results - Emailwire

The proposed Phase 3 trial plan anticipates enrollment of approximately 1,800 patients and 12 months of study drug exposure; BCX4208 administration as add-on treatment to the approved xanthine oxidase (XO) inhibitors, allopurinol or febuxostat; study ...

FDA Panel Nixes Gout Drug - MedPage Today

The panel expressed particular concerns about use of the drug in all patients beginning allopurinol treatment, noting that most clinicians would be likely to reserve rilonacept for patients with severe, tophaceous disease or for patients at high ...

Regeneron Drug’s Benefit May Not Outweigh Risk, FDA Says - Bloomberg

Gout treatments include Takeda Pharmaceutical Co. (4502)’s Uloric and a generic version called allopurinol. They lower levels of uric acid, or bodily waste, that cause gout in excess levels, which manifests through joint pain, according to the ...

FDA Review Has Safety Issues with Gout Drug - MedPage Today

The interleukin (IL)-1 inhibitor rilonacept (Arcalyst) reduces the number of acute gout flares during the vulnerable period while treatment with allopurinol is being started, FDA reviewers found, but they called the drug's safety into question ...

FDA Panel Rejects Regeneron's Arcalyst for Gout - Moneynews (blog)

Gout treatments include Takeda Pharmaceutical Co.’s Uloric and a generic version allopurinol. They lower levels of uric acid, or bodily waste, that cause gout in excess levels, which manifests through joint pain, according to the National ...

Guilt over sudden death of young man - Sun-Journal

It's also responsible for gout. Crystals of uric acid form in the joints when blood uric acid is high. Allopurinol, a medicine that slows uric acid production, or probenecid, a medicine that encourages the passage of uric acid into the urine ...

Zacks Bull and Bear of the Day Highlights: UnitedHealth Group, Citi Trends, AstraZeneca plc, Ardea Biosciences and Takeda Pharmaceutical - Yahoo Finance

The market has a huge unmet need with Takeda Pharmaceutical's (OTC: TKPYY) Uloric (febuxostat) and allopurinol being two widely-prescribed therapies (xanthine oxidase inhibitors) for the treatment of gout patients. The inhibitors reduce the ...

BioCryst Provides Corporate Update and Reports First Quarter 2012 Financial Results - Marketwatch

The proposed Phase 3 trial plan anticipates enrollment of approximately 1,800 patients and 12 months of study drug exposure; BCX4208 administration as add-on treatment to the approved xanthine oxidase (XO) inhibitors, allopurinol or febuxostat ...

Initiating Azathioprine for Crohn's Disease: Management Strategies - Medscape News

Allopurinol competes with xanthine oxidase, shunts metabolism away from 6-MMP production, and increases levels of 6-TGN. The addition of allopurinol may correct an unfavorable ratio of 6-TGN to 6-MMP by reducing 6-MMP concentrations and increasing 6-TGN concentrations.